Asset Manager

Updated:

Arranta Bio Holdings

Arranta Bio Holdings is a Massachusetts-based CDMO specializing in microbiome therapeutics manufacturing, acquired by CaptiveResources LLC in 2023.

Arranta Bio Holdings

Arranta Bio Holdings was established to fill a specific gap in the microbiome therapeutics supply chain: cGMP manufacturing capacity tailored to live biotherapeutic products (LBPs). The firm operates two facilities in Massachusetts — one in Watertown and one in Waltham — that provide process development, analytical development, and clinical/commercial manufacturing services. Its strategy centers on end-to-end support for microbiome drug developers, from strain selection and fermentation through formulation and fill/finish. The company works with clients in the therapeutic, consumer health, and agricultural microbiome spaces. Its asset base includes anaerobic fermentation suites — a technical requirement for many LBPs — and the regulatory expertise needed for phase-appropriate manufacturing. The firm has not publicly disclosed total funding, ownership structure, or team size. In February 2023, Arranta Bio announced that it had been acquired by CaptiveResources LLC, a private holding company. No other recent operational milestones have been publicly reported. Arranta Bio's structural differentiator is its exclusive focus on the microbiome CDMO niche — a narrow but growing segment where traditional contract manufacturers often lack the anaerobic capabilities and regulatory experience required for live biotherapeutic products. That specialization makes it a strategic partner rather than a generalist vendor for microbiome-focused biotechs.

General information

Firm type

Asset Manager

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Watertown

Corporate office

Watertown, MA, United States

Additional offices

Waltham, MA, United States

Sector focus

BiotechPharmaceutical ManufacturingLife SciencesContract Development & Manufacturing OrganizationTherapeuticsMicrobiome

Frequently asked questions

What types of products does Arranta Bio manufacture?

Arranta Bio focuses on live biotherapeutic products (LBPs) — therapies that use live microorganisms to treat, prevent, or cure disease. The firm also serves consumer health and agricultural microbiome companies. Its facilities are designed to handle anaerobic organisms that require oxygen-free environments.

Who owns Arranta Bio?

As of February 2023, Arranta Bio is owned by CaptiveResources LLC, a private holding company that acquired the firm. Prior to that, it operated as an independent CDMO. Its ownership structure is not publicly detailed beyond that acquisition announcement.

What regulatory capabilities does Arranta Bio offer?

Arranta Bio provides phase-appropriate manufacturing under cGMP (current Good Manufacturing Practice) standards. This includes process development, analytical method development, and clinical/commercial manufacturing support tailored to the regulatory requirements of live biotherapeutic products.

Does Arranta Bio only serve human therapeutic clients?

No. While human therapeutics is its primary market, Arranta Bio also serves clients in consumer health and agricultural microbiome applications. The firm's anaerobic fermentation and formulation capabilities apply across these verticals.

Where are Arranta Bio's manufacturing facilities located?

Arranta Bio operates two facilities in Massachusetts — one in Watertown and one in Waltham. Both are designed for microbiome-focused manufacturing, including anaerobic fermentation suites.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo